Which type of products does the Biologics Price Competition and Innovation Act primarily regulate?

• A. Traditional generic small-molecule drugs
• B. Biosimilar and interchangeable biological products
• C. Medical devices
• D. Over-the-counter vitamins

Answer: (B)

The main idea here is how regulatory pathways differ for biologics versus other product types, and which products fall under the Biologics Price Competition and Innovation Act. This act created an abbreviated licensure pathway specifically for biosimilar and interchangeable biological products, under the FDA, to encourage competition while maintaining safety and efficacy oversight for biologics.

Biosimilars are highly similar to a licensed reference biological product, with no clinically meaningful differences in safety, purity, or potency. Interchangeable biological products meet additional criteria and, if designated, can be substituted for the reference product at the pharmacy level in many jurisdictions, subject to state laws.

This is distinct from traditional generic small-molecule drugs, which follow the abbreviated pathway under Hatch-Wers Act (ANDA). It also does not govern medical devices, which use separate device regulatory pathways, nor vitamins or other dietary supplements, which fall outside this biosimilar framework.

Therefore, the products primarily regulated by this act are biosimilar and interchangeable biological products.